Hem › Icke-småcellig lungcancer › Alabama › Birmingham
Kliniska studier för Icke-småcellig lungcancer i Birmingham, AL
22 studier för Icke-småcellig lungcancer söker deltagare vid platser i och runt Birmingham (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
RekryterarFas 3
- Central Alabama Research ( Site 0108), Birmingham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RekryterarFas 3
- Alabama Oncology, Birmingham
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RekryterarFas 3
- Alabama Oncology, St Vincent's Birmingham, Birmingham
- Alabama Oncology, Brookwood, Birmingham
- Alabama Oncology, Princeton, Birmingham
- och 5 fler
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekryterarFas 2
- University of Alabama at Birmingham, Birmingham
Pan-tumor MRD Study
RekryterarObservationsstudie
- Alabama Oncology, Birmingham
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RekryterarFas 1/2
- University of Alabama at Birmingham, Birmingham
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RekryterarFas 3
- Local Institution - 0347, Birmingham
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RekryterarFas 2/3
- Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology, Birmingham
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
RekryterarFas 1/2
- UAB Medicine - UAB Hospital, Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RekryterarObservationsstudie
- University of Alabama at Birmingham, Birmingham
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RekryterarFas 1/2
- The University of Alabama, Birmingham
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
RekryterarFas 1/2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RekryterarFas 1
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RekryterarFas 1
- Uni of Alabama at Birmingham, Birmingham
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RekryterarFas 1
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- och 1 fler
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RekryterarFas 3
- Central Alabama Research, Birmingham
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
RekryterarFas 2
- University of Alabama at Birmingham, Birmingham
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
RekryterarFas 2
- University of Alabama at Birmingham, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Rekryterar
- University of Alabama at Birmingham, Birmingham
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
RekryterarFas 2
- The University of Alabama at Birmingham Hospital, Birmingham
GEMINI-NSCLC: NSCLC Biomarker Study
RekryterarObservationsstudie
- Alabama Oncology, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Birmingham
Icke-småcellig lungcancer-studier i andra städer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andra studier i Birmingham
- Cancer (alla typer)31 studier
- Bröstcancer24 studier
- Äggstockscancer23 studier
- Övervikt23 studier
- Akut myeloid leukemi21 studier
- Multipelt myelom18 studier
- KOL17 studier
- Hjärt-kärlsjukdom17 studier
- Typ 2-diabetes16 studier
- Endometriecancer16 studier
- Övervikt16 studier
- Cystisk fibros16 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.